3 results match your criteria: "and Amsterdam Institute for Immunology and Infectious Diseases[Affiliation]"
Yellow fever breakthrough infections after yellow fever vaccination: a systematic review and meta-analysis.
Lancet Microbe
December 2024
Amsterdam UMC, Location University of Amsterdam, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam Public Health - Global Health, and Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands. Electronic address:
Article Synopsis
- This systematic review and meta-analysis investigated symptomatic yellow fever breakthrough infections in vaccinated individuals, focusing on cases occurring less than and more than ten years after vaccination.
- The research reviewed 1975 records, ultimately identifying 37 relevant studies that documented 6951 yellow fever cases, with 537 involving vaccinated patients, primarily from Brazil.
- A total of 33 confirmed or probable breakthrough cases were found, with two patients severely ill and resulting in death, highlighting a need for ongoing surveillance in vaccinated populations.
Factors associated with acceleration of clinical development for infectious diseases: a cross-sectional analysis of 10-year EMA registration data.
Lancet Reg Health Eur
August 2024
Amsterdam UMC, Location University of Amsterdam, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam Public Health - Global Health, and Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands.
Article Synopsis
- Clinical trials are essential for determining the safety and effectiveness of drugs and vaccines, but they typically take over ten years; however, recent global health emergencies like COVID-19 have shown that these trials can be accelerated.
- A study analyzed drugs targeting infectious diseases authorized by the European Medicines Agency from 2012 to 2022, finding a median clinical development time of 7.3 years, but significantly shorter times for COVID-19 (1.3 years) and Ebola (5.5 years).
- Key factors for faster development included the outbreak context, which reduced time by an average of 5.4 years, and the use of accelerated assessment by the EMA, leading to additional time savings.
The role of the (in)accessibility of social media data for infodemic management: a public health perspective on the situation in the European Union in March 2024.
Front Public Health
April 2024
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, Netherlands.
Public health institutions rely on the access to social media data to better understand the dynamics and impact of an overabundance of information during a disease outbreak, potentially including mis-and disinformation. The scope of the COVID-19 infodemic has led to growing concern in the public health community. The spread of harmful information or information voids may negatively impact public health.
View Article and Find Full Text PDF